Biopharma | April 14, 2026
Gennova CEO Dr Sanjay Singh sees strong innovation momentum for India’s biopharma sector
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
Spread across nearly 4,500 sq. ft., the new clinic combines advanced dental technology, experienced specialists, and an Atithi-first care model
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions
Novo Nordisk continues to position Wegovy as a cornerstone of its obesity treatment portfolio
The approval now covers procedures using 10-14F inner diameter and up to 17F outer diameter procedural sheaths
Final approval for progesterone vaginal inserts expands Glenmark’s women’s healthcare portfolio in the US, targeting a market of over $59 million
Backed by a £680,000 grant from Leeds Hospitals Charity, the study is jointly led by academics and clinicians from the University of Leeds and Leeds Teaching Hospitals NHS Trust
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
Subscribe To Our Newsletter & Stay Updated
